|
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
Nov 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
May 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes |
May 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
Jul 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
Nov 2024 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
Dec 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study |
Jul 2020 |
Leukemia Research |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
Jan 2024 |
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
